ADAP has been the subject of a number of other research reports. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a sell rating to a hold rating in a research report on Friday, August 25th. Leerink Swann reissued an outperform rating and issued a $15.00 price objective on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 8th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a hold rating to a buy rating and set a $5.25 price objective for the company in a research report on Wednesday, July 12th. ValuEngine raised shares of Adaptimmune Therapeutics PLC from a strong sell rating to a sell rating in a research report on Thursday, July 20th. Finally, SunTrust Banks, Inc. reissued a buy rating and issued a $10.00 price objective on shares of Adaptimmune Therapeutics PLC in a research report on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. Adaptimmune Therapeutics PLC currently has an average rating of Hold and a consensus target price of $11.58.
Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at $7.88 on Thursday. Adaptimmune Therapeutics PLC has a twelve month low of $3.76 and a twelve month high of $9.29.
TRADEMARK VIOLATION WARNING: “Adaptimmune Therapeutics PLC (ADAP) Upgraded at TheStreet” was reported by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/markets/adaptimmune-therapeutics-plc-adap-lifted-to-c-at-thestreet/1753410.html.
Hedge funds have recently made changes to their positions in the stock. KCG Holdings Inc. bought a new stake in shares of Adaptimmune Therapeutics PLC during the 1st quarter worth about $133,000. OxFORD Asset Management LLP acquired a new stake in Adaptimmune Therapeutics PLC in the 2nd quarter worth about $156,000. Paloma Partners Management Co acquired a new stake in Adaptimmune Therapeutics PLC in the 1st quarter worth about $165,000. Cubist Systematic Strategies LLC acquired a new stake in Adaptimmune Therapeutics PLC in the 3rd quarter worth about $182,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Adaptimmune Therapeutics PLC in the 3rd quarter worth about $199,000. 67.93% of the stock is owned by institutional investors and hedge funds.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with our FREE daily email newsletter.